[go: up one dir, main page]

ECSP12012234A - Procedimiento - Google Patents

Procedimiento

Info

Publication number
ECSP12012234A
ECSP12012234A ECSP12012234A ECSP12012234A EC SP12012234 A ECSP12012234 A EC SP12012234A EC SP12012234 A ECSP12012234 A EC SP12012234A EC SP12012234 A ECSP12012234 A EC SP12012234A
Authority
EC
Ecuador
Prior art keywords
bag
filled
closed
longitudinal seam
bags
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Gottfried
Joachim Rehse
Werner Heilmann
Michael Lögers
Juergen Stiehl
Saskia Wichmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012234(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of ECSP12012234A publication Critical patent/ECSP12012234A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)

Abstract

Se describen un aparato y métodos para producir bolsas pequeñas (100) a velocidades de producción extremadamente altas llenas de tabaco u otro contenido granulado, en polvo o sólido. Un substrato de banda sinfín (12), con o sin una película de sabor (14) en el mismo, se hace con una forma tubular (29) con una costura longitudinal (106), El tubo (29) se corta en longitudes individuales (10V), y una procesión de tubos se cierra por fruncido en un extremo (102), se llena y se cierra por fruncido en e! otro extremo (104) para completar la producción de bolsas. Durante la producción, las costuras formadas en los extremos fruncidos (102, 104) de la bolsa están paralelas entre sí y la costura longitudinal (106) de la bolsa (100) está a la mitad entre los lados de la bolsa (100) y ortogonal a las costuras formadas en los extremos fruncidos (102, 104) de la bolsa (100).
ECSP12012234 2010-04-15 2012-10-08 Procedimiento ECSP12012234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15

Publications (1)

Publication Number Publication Date
ECSP12012234A true ECSP12012234A (es) 2012-11-30

Family

ID=44070712

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012234 ECSP12012234A (es) 2010-04-15 2012-10-08 Procedimiento

Country Status (40)

Country Link
US (5) US8748622B2 (es)
EP (1) EP2558448B1 (es)
JP (1) JP5934182B2 (es)
KR (2) KR101800041B1 (es)
CN (2) CN102947271B (es)
AR (2) AR081060A1 (es)
AU (1) AU2011240113B2 (es)
BR (1) BR112012026117B1 (es)
CA (1) CA2796238C (es)
CL (1) CL2012002840A1 (es)
CO (1) CO6630136A2 (es)
CR (1) CR20120526A (es)
CU (2) CU24123B1 (es)
DK (1) DK2558448T3 (es)
DO (2) DOP2012000268A (es)
EC (1) ECSP12012234A (es)
ES (1) ES2542610T3 (es)
GT (1) GT201200280A (es)
HK (1) HK1200831A1 (es)
HR (1) HRP20150885T1 (es)
HU (1) HUE026821T2 (es)
IL (2) IL222348B (es)
JO (1) JO3158B1 (es)
MA (1) MA34156B1 (es)
MX (1) MX2012011734A (es)
MY (2) MY177066A (es)
NZ (1) NZ602997A (es)
PE (2) PE20160838A1 (es)
PH (1) PH12012502060A1 (es)
PL (1) PL2558448T3 (es)
PT (1) PT2558448E (es)
RS (1) RS54219B1 (es)
RU (1) RU2581585C2 (es)
SG (2) SG184172A1 (es)
SI (1) SI2558448T1 (es)
TN (1) TN2012000492A1 (es)
TW (2) TWI475992B (es)
UA (1) UA110613C2 (es)
UY (2) UY33290A (es)
WO (1) WO2011128261A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797038B1 (en) * 2004-09-29 2012-06-13 Bayer Pharma Aktiengesellschaft Thermodynamically stable form of bay 43-9006 tosylate
EP1868579B1 (en) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35006A (es) 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
EP2900269B1 (en) 2012-09-25 2018-08-01 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
US9518020B2 (en) 2013-10-04 2016-12-13 Hetero Research Foundation Process for Regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
WO2017125941A1 (en) * 2016-01-18 2017-07-27 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术(石家庄)有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
IL270948B2 (en) 2017-06-02 2025-07-01 Bayer Ag Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003047579A1 (en) 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ES2288694T3 (es) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas.
KR101139557B1 (ko) * 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
DE602005007048D1 (de) 2004-08-27 2008-07-03 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1797038B1 (en) 2004-09-29 2012-06-13 Bayer Pharma Aktiengesellschaft Thermodynamically stable form of bay 43-9006 tosylate
BRPI0515944B1 (pt) 2004-09-29 2021-11-09 Bayer Healthcare Llc Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida
EP1868579B1 (en) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
EP1957069A2 (en) 2005-11-14 2008-08-20 Bayer Healthcare, LLC Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2668748A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 4−[4−({[4−クロロ−3−(トリフルオロメチル)フェニル]カルバモイル}アミノ)−3−フルオロフェノキシ]−n−メチルピリジン−2−カルボキサミドの多形ii
DK2111401T3 (da) 2006-12-20 2011-05-30 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer
WO2008089389A2 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
CA2675979A1 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
JP5439494B2 (ja) 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
JP2012526772A (ja) 2009-05-15 2012-11-01 ノバルティス アーゲー ホスホイノシチド3−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
AU2011310532B2 (en) 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
US20140296301A1 (en) 2011-06-28 2014-10-02 Bayer Pharma Aktiengesellschaft Topical ophthalmological pharmaceutical composition containing regoragenib
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
UY35006A (es) 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib

Also Published As

Publication number Publication date
TW201204356A (en) 2012-02-01
KR101800041B1 (ko) 2017-11-21
TW201509415A (zh) 2015-03-16
CR20120526A (es) 2013-03-11
SG184172A1 (en) 2012-11-29
BR112012026117A2 (pt) 2015-09-08
UY33290A (es) 2011-12-01
SI2558448T1 (sl) 2015-11-30
US8748622B2 (en) 2014-06-10
CU20120147A7 (es) 2013-01-30
WO2011128261A1 (en) 2011-10-20
MY177066A (en) 2020-09-03
KR20130061670A (ko) 2013-06-11
IL222348B (en) 2018-08-30
MX2012011734A (es) 2012-12-17
JP2013523851A (ja) 2013-06-17
JO3158B1 (ar) 2017-09-20
US10822305B2 (en) 2020-11-03
PE20160838A1 (es) 2016-09-24
US20170057918A1 (en) 2017-03-02
IL222348A0 (en) 2012-12-31
EP2558448A1 (en) 2013-02-20
BR112012026117B1 (pt) 2022-08-30
DOP2012000268A (es) 2012-12-15
RS54219B1 (sr) 2015-12-31
PH12012502060A1 (en) 2013-02-04
DOP2016000285A (es) 2016-11-30
AR081060A1 (es) 2012-06-06
SG10201501221UA (en) 2015-04-29
RU2012148386A (ru) 2014-05-20
TN2012000492A1 (en) 2014-04-01
US20190144391A1 (en) 2019-05-16
CN102947271B (zh) 2016-11-09
MA34156B1 (fr) 2013-04-03
CO6630136A2 (es) 2013-03-01
HK1200831A1 (en) 2015-08-14
CU20140060A7 (es) 2014-10-02
UA110613C2 (uk) 2016-01-25
JP5934182B2 (ja) 2016-06-15
CU24123B1 (es) 2015-08-27
PE20130181A1 (es) 2013-02-23
DK2558448T3 (en) 2015-08-24
US20140221661A1 (en) 2014-08-07
TWI539951B (zh) 2016-07-01
BR112012026117A8 (pt) 2017-12-19
EP2558448B1 (en) 2015-05-20
CN102947271A (zh) 2013-02-27
AU2011240113A1 (en) 2012-10-11
CN103980191A (zh) 2014-08-13
MY162359A (en) 2017-06-15
CA2796238C (en) 2019-12-31
HUE026821T2 (en) 2016-07-28
PT2558448E (pt) 2015-09-01
IL253119B (en) 2018-03-29
KR20170129276A (ko) 2017-11-24
US20130116442A1 (en) 2013-05-09
UY39590A (es) 2022-01-31
TWI475992B (zh) 2015-03-11
HRP20150885T1 (hr) 2015-10-09
RU2581585C2 (ru) 2016-04-20
US9458107B2 (en) 2016-10-04
IL253119A0 (en) 2017-08-31
AU2011240113B2 (en) 2014-12-18
GT201200280A (es) 2014-07-23
CA2796238A1 (en) 2011-10-20
AR116395A2 (es) 2021-05-05
NZ602997A (en) 2014-10-31
CL2012002840A1 (es) 2013-01-18
US20170334857A1 (en) 2017-11-23
ES2542610T3 (es) 2015-08-07
PL2558448T3 (pl) 2015-10-30

Similar Documents

Publication Publication Date Title
ECSP12012234A (es) Procedimiento
ECSP12012227A (es) Embolsador de alta velocidad
MX2015014549A (es) Fabricacion de bolsas solubles en agua.
MX2018000795A (es) Bolsa flexible reciclable y metodos para la produccion y uso de esta.
MY169076A (en) Method of forming smoking articles with mouth end cavities
CL2013002386A1 (es) Un conjunto transportador para sujetar un material de banda y moviendo el material de banda a lo largo de una trayectoria, comprende una primera y una segunda correa transportadora sin fin, un dispositivo de pre-insercion de banda y un dispositivo de insercion de correa; y metodo asociado.
GB2557121A8 (en) Medical tubes and methods of manufacture
CL2014000816A1 (es) Sensor de corriente basado en bobina rogowski comprende un tubo de seccion poligonal obtenido a partir de una o mas piezas de pcb rigido que forman caras planas de dicho tubo de seccion poligonal donde se encuentran las espiras que forman la bobina rogowsky y porque la citadas caras planas estan unidas entre si mediante zonas flexibles.
DOP2016000059A (es) Red para hacer unidades llenas de liquido
MX2017002957A (es) Embalaje con refuerzos inferiores y metodo de sellado termico.
CY1119363T1 (el) Συνθετα στεγανωτικα και διαχωριστες πλασματος για σωληνες συλλογης αιματος
ES2570573T3 (es) Procedimiento y dispositivo para fabricar una envoltura de embalaje para productos alimenticios
CY1119936T1 (el) Διαδικασια μορφοποιησης, πληρωσης, σφραγισης για συσκευασια αντικειμενων σε σακουλα πληρωμενη με αερα
ATE519388T1 (de) Zigarettenfilter
ES2196945B1 (es) Lamina para la envoltura de productos alimenticios lista para ser usada y procedimiento de fabricacion de la misma.
AR106160A1 (es) Papel boquilla tramado
AR077787A1 (es) Aparato de empalme de trama y metodo de empalme de trama
ES2192962A1 (es) Procedimiento para la obtencion de un tubular continuo de malla para formacion de bolsas para productos hortofruticolas y similares, y tubular obtenido mediante dicho procedimiento.
ES2527643A1 (es) Método y máquina para empaquetar productos
MX2016001321A (es) Soporte soluble en agua para unir tubos y metodos de fabricacion y uso del mismo.
AR054956A1 (es) Un metodo para la envoltura conjunta de bolsas con su contenido y maquina para ensobrar bolsas segun dicho metodo.
AR085148A1 (es) Metodo para producir envases multiples, y envase correspondiente
EP4144230C0 (en) COOLER POUCH MATERIAL FOR NICOTINE POUCH
CA206370S (en) Snuff pouch with capsule
CA206371S (en) Snuff pouch with capsule